Eisai Launches Lusedra Injection
Eisai has launched Lusedra (fospropofol disodium) injection CIV for use by persons trained in the administration of general anesthesia. Lusedra, an aqueous solution, is an intravenous sedative-hypnotic agent
Vertex has signed a definitive agreement to purchase Crinetics Pharmaceuticals in a transaction valued at nearly $10bn, or $8.8bn net of estimated cash acquired.